Table 2 Haematological and nonhaematological toxicities (cycle 1 and all cycles)

	10–110 mg m^{-2} ($n=7$) grade				150 mg m^{-2} ($n=7$) grade				180 mg m^{-2} ($n=7$) grade			
	1	2	3	4	1	2	3	4	1	2	3	4
Cycle 1												
Leukopenia	2	0	2	0	1	5	1	0	1	1	3	0
Neutropenia	1	0	1	1	0	2	1	3[a]	0	0	3	2[b]
Thrombocytopenia	1	0	0	0	2	0	0	0	4	0	0	0
Hemoglobin	1	0	0	0	2	2	0	0	1	0	0	0
Neuropathy	0	0	0	0	3	0	0	0	3	0	0	0
Myalgia	1	0	0	0	3	0	0	0	2	1	0	0
Arthralgia	1	0	0	0	4	0	0	0	3	0	0	0
Hypersensitivity	0	0	0	0	0	0	0	0	0	1	0	0
Rash	1	0	0	0	1	3	0	0	4	0	0	0
Fatigue	1	0	0	0	5	0	0	0	4	0	0	0
Fever	2	0	0	0	2	0	0	0	1	0	1	0
Anorexia	0	0	0	0	3	0	0	0	1	0	0	0
Nausea	1	0	0	0	1	0	0	0	1	0	0	0
Stomatitis	0	0	0	0	1	0	0	0	1	0	0	0
Alopecia	3	0	—	—	5	0	—	—	5	0	—	—
All cycles												
Leukopenia	3	0	2	0	1	4	2	0	1	1	3	0
Neutropenia	1	0	1	1	1	1	1	4	0	0	3	2
Thrombocytopenia	1	0	0	0	3	0	0	0	4	0	0	0
Hemoglobin	1	0	0	0	1	5	0	0	1	0	0	0
Neuropathy	2	0	0	0	1	3	0	0	4	0	0	0
Myalgia	1	1	0	0	3	0	0	0	2	1	0	0
Arthralgia	2	0	0	0	4	0	0	0	3	0	0	0
Hypersensitivity	0	0	0	0	0	0	0	0	0	1	0	0
Rash	1	0	0	0	3	3	0	0	4	0	0	0
Fatigue	3	0	0	0	5	1	0	0	4	0	0	0
Fever	3	0	0	0	3	1	0	0	1	0	1	0
Anorexia	2	1	0	0	2	1	0	0	2	0	0	0
Nausea	1	0	0	0	1	0	0	0	2	0	0	0
Stomatitis	1	0	0	0	2	0	0	0	1	0	0	0
Alopecia	2	2	—	—	4	3	—	—	4	1	—	—

[a]One of three patients developed DLT, namely grade 4 neutropenia lasting for more than 5 days. [b]These two patients developed DLT, namely grade 4 neutropenia lasting for more than 5 days.

3-week regimen in Japanese patients) (Tamura *et al*, 1995). The V_{ss} and CL_{tot} of NK105 were significantly lower than those of conventional PTX.

The cumulative urinary excretion rates of PTX (0–73 h) after the administration of NK105 were 2.8–9.2%. These values were low, similar to those reported after the administration of conventional PTX (Tamura *et al*, 1995). The CL_r ranged from 11.7 to 66.4 ml h^{-1} m^{-3}, and was slightly decreased with the dose. Since the ratio of CL_r to CL_{tot} was 3–9%, CL_r hardly contributed to CL_{tot}.

Therapeutic response

Six patients (two gastric, two bile duct, one colon, and one pancreatic) were evaluated as having had a stable disease for longer than 4 weeks at the time of the study's completion. A partial response was seen in a patient with metastatic pancreatic cancer who had been treated at 150 mg m^{-2}, and in whom the size of the liver metastasis had decreased by more than 90%, compared to the baseline scan (Figure 3A). This patient had previously undergone treatment with gemcitabine. The antitumour response was maintained for nearly 1 year. In a patient with stomach cancer who was treated at 150 mg m^{-2}, about 40% reduction was observed in a peritoneal metastasis, but a liver metastasis remained stable (Figure 3B).

DISCUSSION

The observed toxicities of NK105 were similar to those expected for conventional PTX. The DLT was neutropenia. The recommended phase II dose using a 3-week schedule was determined to be 150 mg m^{-2}. This recommended dose of NK105 is less than that of conventional PTX (210 mg m^{-2}). Since the plasma AUC of the recommended dose of NK105 was 15- to 20-fold higher than that of the recommended dose of conventional PTX (210 mg m^{-2}), whether the so-called therapeutic window of NK105 is wider than that of conventional PTX should be determined in a future phases II or III trial, although the therapeutic window of NK105 appears to be wider than that of free PTX in mice experiments (Hamaguchi *et al*, 2005).

In general, haematological toxicity was mild and well managed in this trial. PTX is known to cause cumulative peripheral neuropathy resulting in the discontinuation of treatment with PTX. At a dose of 150 mg m^{-2}, three out of seven patients experienced only grade 1 neuropathy during the first cycle. Since the patients enrolled in this trial had almost intractable cancer, such as pancreatic or stomach, a relatively small number of patients received multiple cycles of treatment. Therefore, NK105-related neurotoxicity could not be evaluated in this study. However, three out of four patients who received more than five cycles of treatment experienced transient grade 2 peripheral neuropathy, and other patient developed transient grade 1 peripheral neuropathy. Future phase II trials may clarify whether NK105 is less toxic in terms of peripheral neuropathy when compared with conventional PTX, Abraxane, and other PTX compounds. Another characteristic adverse effect of PTX is hypersensitivity, which may be mainly caused by Cremophor EL. Since NK105 is not formulated in a Cremophor EL-containing solvent, we presumed that hypersensitivity would be diminished.



Figure 2 (**A**) Individual plasma concentrations of PTX in seven patients following 1-h intravenous infusion of NK105 at a dose of 150 mg m^{-2}. (**B**) Relationships between dose and C_{max}, and (**C**) between dose and $AUC_{0-inf.}$ of PTX in patients following 1-h intravenous infusion of NK105. Regression analysis for dose *vs* C_{max} was applied using all points except one patient at 80 mg m^{-2} whose medication time became 11 min longer and one patient at 180 mg m^{-2} who had medication discontinuation and steroid medication. (Plots were shown as open circle). Regression analysis for dose *vs* $AUC_{0-inf.}$ was applied using all points except one patient who had medication discontinuation and steroid medication. (Plot was shown as open circle.) Relationships between dose and C_{max}, and $AUC_{0-inf.}$ in patients following conventional PTX administration were plotted (closed square, see Tamura *et al*, 1995).

Table 3 Pharmacokinetic parameters

	Dose (mg m^{-2})	*n*	C_{max} (μg ml^{-1})	$AUC_{0-inf.}$ (μg h ml^{-1})	$t_{1/2}$ (h)	CL_{tot} (ml h^{-1} m^{-2})	V_{ss} (ml m^{-2})	UE[a] (%)	CL_r (ml h m^{-2})
NK105	10	1	0.9797	11.4	9	880.4	10400.3	7.5	66.4
	20	1	2.8971	29.1	8.5	687.9	8027	8.6	59.4
	40	1	8.8334	93.9	13.2	426.1	5389.8	5.2	22
	80	1	18.4533	149.3	7	535.8	5875.8	4.7	25.3
	110	3	23.3924	232	9.7	483.3	5881.2	7.6	35.6
			±5.6325	±39.1	±1.6	±82.7	±1512.0	±1.7	±6.9
	150	7	40.1699	369.8	10.6	408.6	4527.1	5.3	21.6
			±5.5334	±35.2	±1.3	±37.3	±639.5	±1.5	±6.5
	180	4[b]	45.6278	454.5	11.3	416.5	4983.4	5.9	23.7
			±8.6430	±119.1	±0.6	±104.7	±887.5	±1.4	±4.2

[a]UE, urinary excretion. [b]One patient at 180 mg m^{-2} level was omitted from the calculation of summary pharmacokinetic parameters, as there was administrating interruption for developing allergic reactions.

Indeed, the results of this clinical trial show that NK105 can be administered safely as a short infusion (1 h) without the administration of antiallergic agents like dexamethasone and antihistamine, although one patient at 180 mg m^{-2} developed transient grade 2 hypersensitivity at the first course. Therefore, NK105 may offer advantages in terms of safety and patient convenience and comfort.

The pharmacokinetic analysis of NK105 suggests that the distribution of PTX-incorporating micelles is mostly restricted to the plasma and, in part, to extracellular fluids in the body. This is consistent with data obtained in a preclinical study (Hamaguchi *et al*, 2005) showing that the distribution of NK105 in tissues is characterised by an EPR effect, similar to that of tumour and inflammatory lesions, or by the presence of a reticuloendothelial



Figure 3 Serial CT scans. (**A**) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m^{-2}. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumour response was maintained for nearly 1 year. (**B**) A 64-year-old male with stomach cancer who was treated with NK105 at a dose level of 150 mg m^{-2}. Baseline scan (left panel) showing a peritoneal metastasis and liver metastasis. About 40% reduction (right panel) was observed in peritoneal metastasis, but not in the liver metastasis after fifth course.

Table 4 Pharmacokinetic parameters

	Dose (mg m^{-2})	*n*	C_{max} (μg ml^{-1})	$AUC_{0-Inf.}$ (μg h^{-1} ml^{-1})	$t_{1/2}$ (h)	CL_{tot} (ml h^{-1} m^{-2})	V_{ss} (ml m^{-2})	UE (%)	CL_r (ml h m^{-2})
NK105	150	7	40.1699 ±5.5334	369.8 ±35.2	10.6 ±1.3	408.6 ±37.3	4527.1 ±639.5	5.3 ±1.5	21.6 ±6.5
PTX	210	5	6.744 ±2.733	23.18 ±10.66	13.3 ±1.5	10740 ±4860	58900 ±24700	9.45 ±3.76	1020 ±648
XYOTAX[a]	233	4	NA	1583 ±572	120 ±28	276 ±63	6200 ±2100	NA	NA
Abraxane	300	5	13.52 ±0.95	17.61 ±3.70	14.6 ±2.04	17700 ±3894	370000 ±85100	NA	NA
Genoxol-PM	300	3	3.107 ±1.476	11.58 ±4.28	11.4 ±2.4	29300 ±13800	NA	NA	NA

[a]Conjugated taxanes.

system. When compared with conventional PTX at a dose of 210 mg m^{-2} (conventional dose for a 3-week regimen in Japanese patients), NK105 at a dose of 150 mg m^{-2} (recommended phase II dose) exhibited more than 15-fold larger plasma AUC and a 26-fold lower CL_{tot}. The larger plasma AUC is consistent with the stability of the micelle formulation in plasma. The V_{ss} of NK105 was 13-fold lower than that of conventional PTX. This suggests that PTX may have a relatively lower distribution in normal tissue, including normal neural tissue, following NK105 administration. Regarding the drug distribution in tumours, nanoparticle drug carriers have been known to preferentially accumulate in tumour tissues utilising the EPR effect (Matsumura and Maeda, 1986;

Maeda *et al*, 2000; Duncan, 2003). We speculate that NK105 accumulates more in tumour tissues than free PTX, since NK105 is very stable in the circulation and exhibits a markedly higher plasma AUC than free PTX. Moreover, a polymeric micelle carrier system for a drug has the potential to enable the sustained release of the drug inside a tumour following the accumulation of micelles in the tumour tissue (Hamaguchi *et al*, 2005; Uchino *et al*, 2005; Koizumi *et al*, 2006). Regarding NK105 in particular, this sustained release may begin at a PTX-equivalent dose of $<1\,\mu g\,ml^{-1}$ (data not shown). Consequently, the released PTX is distributed throughout the tumour tissue where it kills the cancer cells directly.

In the present study, NK105 appeared to exhibit characteristic pharmacokinetics different from those of other PTX formulations including conventional PTX, Abraxane, Genexol-PM, and Xyotax. For example, previous clinical PK data at each phase II recommended dose shown that plasma AUC and C_{max} were 11.58 and 3.1 in Genexol-PM (Table 4). The antitumour activities seen in two patients with intractable cancers are encouraging. In addition, we recently demonstrated in preclinical study that combined NK105 chemotherapy with radiation exerts a significantly more potent antitumour activity, compared with combined PTX therapy and radiation (Negishi *et al*, 2006). This data on NK105 justifies its continued clinical evaluation.

Clinical Studies

ACKNOWLEDGEMENTS

We thank the patients who participated in this trial. We also thank Kaoru Shiina and Hiromi Orita for their secretarial assistance.

REFERENCES

Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. *Clin Cancer Res* **11**: 7834–7840

Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. *Semin Oncol* **23**: 71–75

Crown J, O'Leary M (2000) The taxanes: an update. *Lancet* **355**: 1176–1178

Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. *26th Annual San Antonio Breast Cancer Symposium* San Antonio, TX

Duncan R (2003) The dawning era of polymer therapeutics. *Nat Rev Drug Discov* **2**: 347–360

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* **23**: 7794–7803

Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend *in vivo* antitumour activity and reduce the neurotoxicity of paclitaxel. *Br J Cancer* **92**: 1240–1246

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. *Clin Cancer Res* **8**: 1038–1044

Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. *Clin Cancer Res* **10**: 3708–3716

Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. *Br J Cancer* **90**: 304–305

Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. *Cancer Res* **66**: 10048–10056

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *J Control Release* **65**: 271–284

Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. *Cancer Res* **46**: 6387–6392

Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. *Br J Cancer* **91**: 1775–1781

Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y (2006) NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. *Br J Cancer* **95**: 601–606

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. *J Clin Oncol* **23**: 7785–7793

Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). *New Engl J Med* **332**: 1004–1014

Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. *J Natl Cancer Inst* **82**: 1247–1259

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. *J Natl Cancer Inst* **89**: 1138–1147

Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P (2003) Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. *Adv Exp Med Biol* **519**: 81–99

Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. *Jpn J Cancer Res* **86**: 1203–1209

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* **92**: 205–216

Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. *Br J Cancer* **93**: 678–687

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. *J Clin Oncol* **8**: 1263–1268

Journal of Drug Targeting, August–September 2007; 15(7–8): 507–517

informa
healthcare

Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles

YASUHIRO MATSUMURA

Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Abstract
Tumour-targeted delivery of therapeutic agents is a longstanding pharmacological goal to improve selectivity and Therapeutic Index. Most scientists have sought to use 'active' receptor-mediated tumour-targeting systems, however the 'passive' targeting afforded by the Enhanced Permeability and Retention (EPR) effects provides a versatile and non-saturable opportunity for tumour-selective delivery. Polymeric micelles are ideally suited to exploit the EPR effect, and they have been used for the delivery of a range of anticancer drugs in preclinical and clinical studies. Here I overview some of the more important approaches, assessing usefulness and seeking to identify the most promising ways to apply the phenomenon of passive targeting for improved clinical outcome.

Keywords: *Micelles, anticancer agent, EPR effect, clinical trial*

Preface

Several problems of anticancer agents are recognized, such as their low therapeutic indices and limited efficacy due to the nonselective nature of their therapeutic targets and their inability to accumulate selectively in cancer tissues. Therefore, it would be desirable to develop modalities by which cytotoxic drugs can be selectively targeted to tumour tissues and allowed to act effectively on only the cancer cells in the tumor. The role of drug delivery systems (DDS) has drawn attention in this context. DDS could be used for active or passive targeting of tumor tissues. The former refers to the development of monoclonal antibodies directed against tumour-related molecules that allow targeting of the tumour, because of specific binding between the antibody and its antigen. However, the application of DDS using monoclonal antibodies is restricted to tumours expressing high levels of related antigens.

About a quarter of a century ago, after training as a surgeon, I started my career in the field of DDS under the supervision of Prof. Maeda. We made intensive efforts to ascertain the mechanism of accumulation of macromolecules in solid tumours. Finally, we succeeded in publishing the first paper, in 1986, on the enhanced permeability and retention (EPR) effect (Matsumura and Maeda 1986). Passive targeting is based on this EPR effect. The EPR effect is based on the pathophysiological characteristics of solid tumour tissues: hypervascularity, incomplete vascular architecture, secretion of vascular permeability factors stimulating extravasation within cancer tissue, and absence of effective lymphatic drainage from tumours that impedes the efficient clearance of macromolecules accumulated in solid tumour tissues.

Several techniques to maximally use the EPR effect have been developed, e.g. modification of drug structures and development of drug carriers. Polymeric micelle-based anticancer drugs were originally developed by Prof. Kataoka et al. in late the 1980's or early 1990's (Yokoyama et al. 1990; 1991a, b, c; Kataoka et al. 1993). Polymeric micelles were expected to increase the accumulation of drugs in tumour tissues utilizing the EPR effect and to incorporate various kinds of drugs into the inner core by chemical conjugation or physical entrapment with relatively high stability. The size of the micelles

Correspondence: Y. Matsumura, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

ISSN 1061-186X print/ISSN 1029-2330 online
DOI: 10.1080/10611860701499888

can be controlled within the diameter range of 20–100 nm, to ensure that the micelles do not pass through normal vessel walls; therefore, a reduced incidence of the side effects of the drugs may be expected due to the decreased volume of distribution.

In this chapter, polymeric micelle systems for which clinical trials are now underway are reviewed.

NK105, paclitaxel-incorporating micellar nanoparticle

Paclitaxel (PTX) is one of the most useful anticancer agents known for various cancers, including ovarian, breast and lung cancers (Carney 1996; Khayat et al. 2000). However, PTX has serious adverse effects, e.g. neutropenia and peripheral sensory neuropathy. In addition, anaphylaxis and other severe hypersensitive reactions have been reported to develop in 2–4% of patients receiving the drug even after premedication with antiallergic agents; these adverse reactions have been attributed to the mixture of Cremophor EL and ethanol which was used to solubilize PTX (Weiss et al. 1990; Rowinsky and Donehower 2003). Of the adverse reactions, neutropenia can be prevented or managed effectively by administering a granulocyte colony-stimulating factor. On the other hand, there are no effective therapies to prevent or reduce nerve damage which is associated with peripheral neuropathy caused by PTX; therefore, neurotoxicity constitutes a significant dose-limiting toxicity (DLT) of the drug (Rowinsky et al. 1993; Wasserheit et al. 1996).

Preparation and characterization of NK105

To construct NK105 micellar nanoparticles (Figure 1), block copolymers consisting of polyethylene glycol (PEG) and polyaspartate, so-called PEG-polyaspartate described previously (Yokoyama et al. 1990; 1991a, b, c; Kataoka et al. 1993), were used. PTX was incorporated into polymeric micelles formed by physical entrapment utilizing hydrophobic interactions between PTX and the block copolymer polyaspartate chain. After screening of many candidate substances, 4-phenyl-1-butanol was employed for the chemical modification of the polyaspartate block to increase its hydrophobicity. Treating with a condensing agent, 1,3-diisopropylcarbodiimide, the half of carboxyl groups on the polyaspartate were esterified with 4-phenyl-1-butanol. Molecular weight of the polymers was determined to be approximately 20,000, (PEG block: 12,000; modified polyaspartate block: 8000). NK105 was prepared by facilitating the self-association of NK105 polymers and PTX. NK105 was obtained as a freeze-dried formulation and contained *ca.* 23% (w/w) of PTX, as determined by reversed-phase liquid-chromatography using an ODS column with mobile phase consisting of acetonitrile and water (9:11, v/v) and detection of ultraviolet absorbance at 227 nm. Finally, NK105, a PTX-incorporating polymeric micellar nanoparticle formulation with a single and narrow size distribution, was obtained. The weight-average diameter of the nanoparticles was approximately 85 nm ranging from 20 to 430 nm.



Figure 1. Preparation and characterization of NK105. The micellar structure of NK105 PTX was incorporated into the inner core of the micelle.

Pharmacokinetics and pharmacodynamics of NK105

Colon 26-bearing CDF1 mice were given a single iv injection of PTX 50 or 100 mg/kg, or of NK105 at an equivalent dose of PTX. Subsequently, the time-course changes in the plasma and tumour levels of PTX were determined in the PTX and NK105 administration groups; furthermore, the pharmacokinetic parameters of each group were also determined. NK105 exhibited slower clearance from the plasma than PTX, while NK105 was present in the plasma for up to 72 h after injection; PTX was not detected after 24 h or later of injection. The plasma concentration at 5 min ($C_{5\,min}$) and the AUC of NK105 were 11- to 20-fold and 50- to 86-fold higher for NK105 than for PTX, respectively. Furthermore, the half-life at the terminal phase ($t_{1/2}z$) was 4–6 times longer for NK105 than for PTX. The maximum concentration (C_{max}) and AUC of NK105 in Colon 26 tumours were approximately 3 times and 25 times higher for NK105 than for PTX, respectively. NK105 continued to accumulate in the tumours until 72 h after injection. The tumour PTX concentration was higher than 10 μg/g even at 72 h after the intravenous injection of NK105 50 and 100 mg/kg. By contraries, the tumour PTX concentrations at 72 h after the intravenous administration of free PTX 50 and 100 mg/kg were below detection limits and less than 0.1 μg/g, respectively.

In vivo *antitumour activity*

BALB/c mice bearing s.c. HT-29 colon cancer tumours showed decreased tumour growth rates after the administration of PTX and NK105. However, NK105 exhibited superior antitumour activity as compared with PTX ($P < 0.001$). The

antitumour activity of NK105 administered at a PTX-equivalent dose of 25 mg/kg was comparable to that obtained after the administration of free PTX 100 mg/kg. Tumour suppression by NK105 increased in a dose-dependent manner. Tumours disappeared after the first dosing to mice treated with NK105 at a PTX-equivalent dose of 100 mg/kg, and all mice remained tumour-free thereafter. In addition, less weight loss was induced in mice which were given NK105 100 mg/kg than in those which were given the same dose of free PTX.

Neurotoxicity of PTX and NK105

Treatment with PTX has resulted in cumulative sensory-dominant peripheral neurotoxicity in humans, characterized clinically by numbness and/or paraesthesia of the extremities. Pathologically, axonal swelling, vesicular degeneration, and demyelination were observed. We, therefore, examined the effects of free PTX and NK105 using both electrophysiological and morphological methods.

Prior to drug administration, there were no significant differences in the amplitude of caudal sensory nerve action potential (caudal SNAP) between two drug administration groups. On day 6 after the last dosing (at week 6), the amplitude of the caudal SNAP in the control group increased in association with rat maturation. The amplitude was significantly smaller in the PTX group than in the control group ($P < 0.01$), while the amplitude was significantly larger in the NK105 group than in the PTX group ($P < 0.05$) and was comparable between the NK105 group and the control group (Figure 2). Histopathological examination of longitudinal paraffin-embedded sections of the sciatic nerve 5 days after the sixth weekly injection revealed degenerative changes. The NK105 administration group showed only a few degenerative myelinated fibers in contrast to the PTX administration group which indicated markedly more numerous degenerative myelinated fibers.



Figure 2. Effects of PTX or NK105 on the amplitude of rat caudal sensory nerve action potentials as examined 5 days after weekly injections for 6 weeks. Rats ($n = 14$) were injected with NK105 or PTX at a PTX-equivalent dose of 7.5 mg/kg. About 5% glucose was also injected in the same manner to animals in the control group.

Clinical study

A phase I study was designed to determine maximum tolerated dose (MTD), DLTs, the recommended dose (RD) for phase II and the pharmacokinetics of NK105 (Kato et al.).

NK105 was administered by 1-hour intravenous infusion every 3 weeks without anti-allergic premedication. The starting dose was 10 mg PTX equivalent/m^2, and dose escalated according to the accelerated titration method. To date, 17 patients (pts) have been treated at the following doses: 10 mg/m^2 ($n = 1$); 20 mg/m^2 ($n = 1$); 40 mg/m^2 ($n = 1$); 80 mg/m^2 ($n = 1$); 110 mg/m^2 ($n = 3$); 150 mg/m^2 ($n = 5$); 180 mg/m^2 ($n = 5$). Tumor types treated have included: pancreatic ($n = 9$), bile duct ($n = 5$), gastric ($n = 2$), and colon ($n = 1$). Neutropenia has been the predominant hematological toxicity and grade 3 or 4 neutropenia was observed in pts treated at 110, 150 and 180 mg/m^2. One patient at 180 mg/m^2 developed grade 3 fever. No other grade 3 or 4 non-hematological toxicity including neuropathies was observed. DLTs were observed in pts with at the 180 mg/m^2 (grade 4 neutropenia lasting for more than 5 days), which was determined as MTD. Allergic reactions were not observed in any of the patients except one patient at the 180 mg/m^2. A partial response was observed in one pancreatic cancer pt who received more than 12 courses of NK105 (Figure 3). Despite of the long time usage, only grade 1 or 2 neuropathy was observed by modifying the dose or period of drug administration. Colon and gastric cancer pts experienced stable disease lasting 10 and 7 courses, respectively. The C_{max} and AUC of NK105 showed dose-dependent characteristics. The plasma AUC of NK105 at 180 mg/m^2 was approximately 30-fold higher than that of commonly-used paclitaxel formulation.

Accrual is ongoing at the 150 mg/m^2 dose level to determine RD. DLT was grade 4 neutropenia. NK105 generates prolonged systemic exposure to PTX in plasma. Tri-weekly 1-hour infusion of NK105 was feasible and well tolerated, with antitumor activity in pancreatic cancer pt. NK105 is planning to be evaluated in Phase II studies of patients with pancreatic, gastric, or ovarian cancer.

NC-6004, cisplatin-incorporating micellar nanoparticle

Cisplatin [*cis*-dichlorodiammineplatinum (II): CDDP] is a key drug in the chemotherapy for cancers, including lung, gastrointestinal, and genitourinary cancer (Roth 1996; Horwich et al. 1997). However, we often find that it is necessary to



Figure 3. Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg/m^2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumor response was maintained for nearly 1 year.

discontinue treatment with CDDP due to its adverse reactions, e.g. nephrotoxicity and neurotoxicity, despite its persisting effects (Pinzani et al. 1994). Platinum analogues, e.g. carboplatin and oxaliplatin (Cleare et al. 1978), have been developed to date to overcome these CDDP-related disadvantages. Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al. 2003) and colon cancer (Cassidy et al. 2004). However, those regimens including CDDP are considered to constitute the standard treatment for lung cancer, stomach cancer, testicular cancer (Horwich et al. 1997), and urothelial cancer (Bellmunt et al. 1997). Therefore, the development of a DDS technology is anticipated, which would offer the better selective accumulation of CDDP into solid tumours while lessening its distribution into normal tissue.

Preparation and characterization of NC-6004

NC-6004 were prepared according to the slightly modified procedure reported by Nishiyama et al. (2003) (Figure 4). NC-6004 consists of PEG, a hydrophilic chain which constitutes the outer shell of the micelles, and the coordinate complex of poly(glutamic acid) (P(Glu)) and CDDP, a polymer-metal complex-forming chain which constitutes the inner core of the micelles. The molecular weight of PEG-P(Glu) as a sodium salt was approximately 18,000 (PEG: 12,000; P(Glu): 6000). The CDDP-incorporated polymeric micelles were clearly discriminated from typical micelles from amphiphilic block copolymers. The driving force of the formation of the CDDP-incorporated micelles is the ligand substitution of platinum(II) atom from chloride to carboxylate in the side chain of P(Glu). The molar ratio of CDDP to the carboxyl groups in the copolymers was 0.71 (Nishiyama et al. 2003). A narrowly distributed size of polymeric micelles (30 nm) was confirmed by the dynamic light scattering (DLS) measurement. Also, the static light scattering (SLS) measurement revealed that the CDDP-loaded micelles showed no dissociation upon dilution and the CMC was less than 5×10^{-7}, suggesting remarkable stability compared with typical micelles from amphiphilic block copolymers (Nishiyama et al. 2003). It is assumed that the interpolymer cross-linking by Pt(II) atom might contribute to stabilization of the micellar structure.

The release rates of CDDP from NC-6004 were 19.6 and 47.8% at 24 and 96 h, respectively. In distilled water, furthermore, NC-6004 was stable without releasing cisplatin.

Pharmacokinetics and pharmacodynamics

FAAS could measure serum concentrations of platinum up to 48 h after i.v. injection of NC-6004 but could measure them only up to 4 h after i.v. injection of CDDP. NC-6004 showed a very long blood retention profile as compared with CDDP. The AUC_{0-t} and C_{max} values were significantly higher in animals given NC-6004 than in animals given CDDP, namely, 65-fold and 8-fold, respectively, ($P < 0.001$ and 0.001, respectively). Furthermore, the CL_{tot} and Vss values were significantly lower in animals given NC-6004 than in animals given



Figure 4. Preparation and characterization of cisplatin-incorporating polymeric micelles (NC-6004). Chemical structures of cisplatin (CDDP) and polyethylene glycol poly(glutamic acid) block copolymers [PEG-P(Glu) block copolymers], and the micellar structures of CDDP-incorporating polymeric micelles (NC-6004).

CDDP, i.e. one-nineteenth and one-seventy fifth, respectively, ($P < 0.01$ and 0.01, respectively).

Regarding the concentration–time profile of platinum in various tissues after i.v. injection of CDDP or NC-6004, all organs measured exhibited the highest concentrations of platinum within 1 h after administration in all animals given CDDP. Furthermore, animals given NC-6004 exhibited the highest tissue concentrations of platinum in the liver and spleen at late time points (24 and 48 h after administration, respectively). However, the concentrations decreased on day 7 after administration. In addition, and in a similar manner to other drugs, which are incorporated in polymeric carriers, NC-6004 demonstrated accumulation in organs of the reticuloendothelial system, e.g. liver and spleen. At 48 h after administration, tissue concentrations of platinum in the liver and spleen were 4.6- and 24.4-fold higher for NC-6004 than for CDDP. On the other hand, a marked increase in tissue platinum concentration was observed immediately after administration in the kidneys of animals given CDDP. Renal platinum concentration at 10 min and 1 h after administration were 11.6- and 3.1-fold lower, respectively, in animals given NC-6004 than in animals given CDDP. Furthermore, the maximum concentration (C_{max}) in the kidney was 3.8-fold lower at the time of NC-6004 administration than at the time of CDDP administration.

Regarding the tumour accumulation of platinum, tumour concentrations of platinum peaked at 10 min after administration of CDDP. On the other hand, tumour concentrations of platinum peaked at 48 h after administration of NC-6004. The maximum concentration (C_{max}) in tumour was 2.5-fold higher for NC-6004 than for CDDP ($P < 0.001$). Furthermore, the tumour AUC was 3.6-fold higher for NC-6004 than for CDDP (81.2 and 22.6 μg/ml h in animals given NC-6004 and CDDP, respectively).

In vivo *antitumour activity*

BALB/c nude mice implanted with a human gastric cancer cell line MKN-45 showed decreased tumour growth rates after i.v. injection of CDDP and NC-6004. In the administration of CDDP, the CDDP 5 mg/kg administration group showed a significant decrease ($P < 0.01$) in tumour growth rate as compared with the control group. However, the NC-6004 administration groups at the same dose levels as CDDP showed no significant difference in tumour growth rate. Regarding time-course changes in body weight change rate, the CDDP 5 mg/kg administration group showed a significant decrease ($P < 0.001$) in body weight as compared with the control group. On the other hand, NC-6004 administration group did not show a decrease in body weight as compared with the control group.

Nephrotoxicity of CDDP and NC-6004

In the CDDP 10 mg/kg administration group, 4 of 12 rats died from toxicity within 7 days after drug administration. No deaths occurred in the NC-6004 10 mg/kg administration group. Regarding renal function, the BUN concentrations on day 7 after the administration of 5% glucose, CDDP 10 mg/kg, and NC-6004 10 mg/kg were 20.8 ± 3.0, 65.3 ± 44.4 and 20 ± 4.5 mg/dl, respectively. The plasma concentrations of creatinine on day 7 after the administration of 5% glucose, CDDP 10 mg/kg, and NC-6004 10 mg/kg were 0.27 ± 0.03, 0.68 ± 0.23 and 0.28 ± 0.04 mg/dl, respectively. The CDDP 10 mg/kg administration group showed significantly higher plasma concentrations of BUN and creatinine as compared with the control group ($P < 0.05$ and 0.001, respectively), with the NC-6004 10 mg/kg administration group ($P < 0.05$ and 0.001, respectively) (Figure 5). Light microscopy indicated tubular dilation with flattening of the lining cells of the tubular epithelium in the kidney from all animals in the CDDP 10 mg/kg administration group. On the other hand, no histopathological change was observed in the kidneys from all animals in the NC-6004 10 mg/kg administration group.

Neurotoxicity of CDDP and NC-6004

Neurophysiological examination revealed that motor nerve conduction velocities (MNCVs) in animals given 5% glucose, CDDP, and NC-6004 were 44.2 ± 3.5, 40.94 ± 5.08 and 40.62 ± 0.63 m/s, respectively. No significant difference was found among the groups with respect to MNCV. Furthermore, sensory nerve conduction velocities (SNCVs) in animals given 5% glucose, CDDP, and NC-6004 were 42.86 ± 8.07, 35.48 ± 4.91 and 43.74 ± 5.3 m/s, respectively. Animals given NC-6004 showed no delay in SNCV as compared with animals given 5% glucose. On the other hand, animals given CDDP showed a significant delay ($P < 0.05$) in SNCV as compared with animals given NC-6004 (Figure 6). The analysis by ICP-MS on sciatic nerve concentrations of platinum could not detect platinum in the sciatic nerve from animals given 5% glucose (data not shown). Sciatic nerve concentrations of platinum



Figure 5. Nephrotoxicity of CDDP and NC-6004. Plasma concentrations of blood urea nitrogen (BUN) and creatinine were measured after a single i.v. injection of 5% glucose ($n = 8$), CDDP at a dose of 10 mg/kg ($n = 12$), NC-6004 at a dose of 10 mg/kg ($n = 13$) on a CDDP basis.



Figure 6. Neurotoxicity of CDDP and NC-6004 in rats. Rats ($n = 5$) were given CDDP (2 mg/kg), NC-6004 (an equivalent dose of 2 mg/kg CDDP), or 5% glucose, all intravenously twice a week, 11 administrations in total. Sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) of the sciatic nerve at week 6 after the initial administration. The platinum concentration in the sciatic nerve. Rats were given CDDP (5 mg/kg, $n = 5$), NC-6004 (an equivalent dose of 5 mg/kg CDDP, $n = 5$), or 5% glucose ($n = 2$), all intravenously twice a week, four administrations in total. On day 3 after the final administration, a segment of the sciatic nerve was removed and the platinum concentration in the sciatic nerve was measured by ICP-MS. The data are expressed as the mean ± SD $*P < 0.05$.

in animals given CDDP and NC-6004 were 827.2 ± 291.3 and 395.5 ± 73.1 ng/g tissue. Therefore, the concentrations were significantly ($P < 0.05$) lower in animals given NC-6004. This finding is believed to be a factor which reduced neurotoxicity following NC-6004 administration as compared with the CDDP administration.

Present situation of a clinical study of NC-6004

A phase 1 clinical trial of NC-6004 is now under way in United Kingdom. Starting dose of NC-6004 was 10 mg/m^2. NC-6004 was administered once every 3 weeks with only 1000 ml water loading. In Japan, a phase 1 trial will be stared soon in the National Cancer Center Hospital.

NK012, SN-38-incorporating micellar nanoparticle

The antitumor plant alkaloid camptothecin (CPT) is a broad-spectrum anticancer agent which targets the DNA topoisomerase I. Although CPT has showed promising antitumor activity *in vitro* and *in vivo* (Gallo et al. 1971; Li et al. 1972), it has not been used clinically because of its low therapeutic efficacy and severe toxicity (Gottlieb et al. 1970; Muggia et al. 1972). Among CPT analogs, irinotecan hydrochloride (CPT-11) has recently been demonstrated to be active against colorectal, lung, and ovarian cancer (Cunningham et al. 1998; Saltz et al. 2000; Noda et al. 2002, Negoro et al. 2003; Bodurka et al. 2003). CPT-11 itself is a prodrug and is converted to 7-ethyl-10-hydroxy-CPT (SN-38), a biologically active metabolite of CPT-11, by carboxylesterases (CEs). SN-38 exhibits up to 1000-fold more potent cytotoxic activity against various cancer cells *in vitro* than CPT-11 (Takimoto and Arbuck 2001). Although CPT-11 is converted to SN-38 in the liver and tumor, the metabolic conversion rate is less than 10% of the original volume of CPT-11 (Rothenberg et al. 1993; Slatter et al. 2000). In addition, the conversion of CPT-11 to SN-38 depends on the genetic interindividual variability of CE activity (Guichard et al. 1999). Thus, direct use of SN-38 might be of great advantage and attractive for cancer treatment. For the clinical use of SN-38, however, it is essential to develop a soluble form of water-insoluble SN-38. The progress of the manufacturing technology of "micellar nanoparticles" may make it possible to use SN-38 for *in vivo* experiments and further clinical use.

Preparation and characterization of NK012

NK012 is an SN-38-loaded polymeric micelle constructed in an aqueous milieu by the self-assembly of an amphiphilic block copolymers, PEG-PGlu(SN-38). The molecular weight of PEG-PGlu(SN-38) was determined to be approximately 19,000 (PEG segment: 12,000; SN-38-conjugated PGlu segment: 7000). NK012 was obtained as a freeze-dried formulation and contained *ca.* 20% (w/w) of SN-38 (Figure 7). The mean particle size of NK012 is 20 nm in diameter with a relatively narrow range. The releasing rates of SN-38 from NK012 in phosphate buffered saline at 37°C were 57 and 74% at 24 and 48 h, respectively, and that in 5% glucose solution at 37°C were 1 and 3% at 24 and 48 h, respectively. These results indicate that NK012 can release SN-38 under neutral condition even without the presence of a hydrolytic enzyme, and is stable in 5% glucose solution. It is suggested that NK012 is stable before administration and starts to release SN-38, the active component, under physiological conditions after administration.

Cellular sensitivity of NSCLC and colon cancer cells to SN-38, NK012, and CPT-11

The IC_{50} values of NK012 for the cell lines ranged from 0.009 μM (Lovo cells) to 0.16 μM (WiDR cells). The growth-inhibitory effects of NK012 are 43–340 fold more potent than those of CPT-11, whereas the IC_{50} values of NK012 were 2.3–5.8 fold higher than those of SN-38.NK012 exhibited a higher cytotoxic effect against each cell line as compared with CPT-11 (× 43–340 fold sensitivity). On the other hand, the IC_{50} values of NK012 were a little higher than those of SN-38, similar to the cytotoxic feature also reported in a previous study about micellar drugs (Uchino et al. 2005).

Pharmacokinetic analysis of NK012 and CPT-11 using HT-29-bearing nude mice

After injection of CPT-11, the concentrations of CPT-11 and SN-38 for plasma declined rapidly with time in a log-linear fashion. On the other hand, NK012 (polymer-bound SN-38) exhibited slower clearance. The clearance of NK012 in the HT-29 tumor was significantly slower and the concentration of free SN-38 was maintained at more than 30 ng/g even at 168 h after injection.

Anti-tumor activity and the distribution of NK012 and CPT-11 in SBC-3/Neo or SBC-3/VEGF tumors

In order to determine whether the potent antitumor effect of NK012 is enhanced in the tumors with high vascularity, we used vascular endothelial growth factor-secreting cells SBC-3/VEGF. There was no significant difference in the *in vitro* cytotoxic activity of each drug between SBC-3/Neo and SBC-3/VEGF. Gross findings of SBC-3/VEGF tumors are reddish as compared with SBC-3/Neo tumors. Deviating from the ordinary experimental tumor model, tumors were allowed to



Figure 7. Schematic structure of NK012. A polymeric micelle carrier of NK012 consists of a block copolymer of PEG (molecular weight of about 5000) and partially modified polyglutamate (about 20 unit). Polyethylene glycol (hydrophilic) is believed to be the outer shell and SN-38 was incorporated into the inner core of the micelle.

grow until they became massive in size, around 1.5 cm (Figure 8), and then the treatment was initiated. NK012 at doses of 15 and 30 mg/kg showed potent anti-tumor activity against bulky SBC-3/Neo tumors (1533.1 ± 1204.7 mm^3) as compared with CPT-11 (Figure 8). Striking antitumor activity was observed in mice treated with NK012 (Figure 8) when we compared the antitumor activity of NK012 with CPT-11 using SBC-3/VEGF cells. SBC-3/VEGF bulky masses (1620.7 ± 834.0 mm^3) disappeared in all mice, although relapse 3 months after treatment was noted in one mouse treated with NK012 20 mg/kg (Figure 8). On the other hand,



Figure 8. Intravenous administration of NK012 or CPT-11 was started when the mean tumor volumes of groups reached a massive 1500 mm^3. The mice were divided into test group (□: control; □: CPT-11 20 mg/kg/day; □: CPT-11 40 mg/kg/day; ▲: NK012 15 mg/kg/day; and □: NK012 30 mg/kg/day). NK012 or CPT-11 was administered i.v. on days 0, 4 and 8. Each group consisted of 4 mice. $*P < 0.05$.

SBC-3/VEGF were not eradicated and rapidly regrew after a partial response in mice treated with CPT-11. Approximate 10% body weight loss was observed in mice treated with NK012 20 mg/kg, but no significant difference was observed in comparison with mice treated with CPT-11 30 mg/kg.

We then examined the distribution of free SN-38 in the SBC-3/Neo and SBC-3/VEGF masses after administration of NK012 and CPT-11. In the case of CPT-11 administration, the concentrations at 1 and 6 h after the administration were less than 100 ng/g both in the SBC-3/Neo and SBC-3/VEGF tumors, and were almost negligible at 24 h in both tumors. There was no significant difference in the concentration between the SBC-3/Neo and SBC-3/VEGF tumors. On the other hand, in the case of NK012 administration, free SN-38 was detectable in the tumors even at 72 h after the administration. The concentrations of free SN-38 were higher in the SBC-3/VEGF tumors than those in the SBC-3/Neo tumors at any time point during the period of observation (significant at 1, 6, 24 h. $*P < 0.05$).

Tissue distribution of SN-38 after administration of NK012 and CPT-11

We examined the concentration–time profile of free SN-38 in various tissues after i.v. administration of NK012 and CPT-11. All organs measured exhibited the highest concentration of SN-38 at 1 h after administration in mice given CPT-11. On the other hand, mice given NK012 exhibited prolonged distribution in the liver and spleen. In a similar manner to other micellar drugs (Yokoyama et al. 1991a, b, c; Uchino et al. 2005), NK012 demonstrated relatively higher accumulation in organs of the reticuloendothelial system. In the lung, kidney and small intestine, the highest concentration of free SN-38 was achieved at 1 h after injection of NK012 and the concentration was almost negligible at 24 h. Although the concentrations of free SN-38 in the small intestine were relatively high at 1 h after administration of NK012 and CPT-11, those rapidly decreased. Interestingly, there was no significant difference in the kinetic character of free SN-38 in the small intestine between mice treated with NK012 and CPT-11.

Synergistic antitumour activity of the NK012 combined with 5-fluorouracil

In two phase III trials, the addition of CPT-11 to bolus or infusional 5FU/LV regimens clearly yielded greater efficacy than treatment with 5FU/LV alone, with a doubling of the tumor response rate and prolongation of the median survival time by 2–3 months (Douillard et al. 2000; Saltz et al. 2001).

We demonstrated that the novel SN-38-incorporating polymeric micelles, NK012, exerted superior antitumor activity and less toxicity as compared to CPT-11 (Koizumi et al. 2006). Therefore, we speculated that the use of NK012 in place of CPT-11 in combination with 5FU may also yield superior results.

Comparison of the antitumor effect of combined NK012/5FU and CPT-11/5FU. The therapeutic effect of CPT-11/5FU was apparently inferior to that of NK012/5FU or even NK012 alone at the MTD. A more potent antitumor effect, namely 100% CR rate, was obtained in the NK012 alone and NK012/5FU groups, as compared with the 0% CR rate in the CPT-11/5FU (Nakajima and Matsumura 2007).

Specificity of cell cycle perturbation. We studied the difference in the effects between NK012 and CPT-11 on the cell cycle. The data indicate that both NK012 and CPT-11 had a tendency to accumulate the cells in the S phase, although the effect of NK012 was stronger and maintained for a more prolonged period than that of CPT-11. The histograms show aneuploidy of the tumor and that administration of NK012 or CPT-11 caused apoptosis of a proportion of the tumor cells (Nakajima and Matsumura 2007).

Present situation of a clinical study of NK012

A phase 1 study of NK012 is now under way in the National Cancer Center, Tokyo and Kashiwa in patients with advanced solid tumours. NK012 is infused intravenously over 60 min every 21 days until disease progression or unacceptable toxicity occurs.

Conclusion

A quarter of a century has passed since the EPR effect was discovered (Matsumura and Maeda 1986). Now the phrase EPR has become a fundamental principle in the field of DDS. Until recently, the EPR had not been recognized in the field of oncology. However, many oncologists have now become acquainted with it, since some drugs such as doxil, abraxane, and several PEGylated proteinacious agents formulated based on the EPR have been approved in the field of oncology. Micelle carrier systems described in this chapter are obviously categorized as DDS based on the EPR. I believe that some anticancer agents incorporating micelle nanoparticles may be approved for clinical use soon.

Our next task is to develop DDS utilizing the EPR effect, which can accumulate selectively in solid tumours but also allow distribution of the delivered

bullets (anticancer agents) through the entire mass of the solid tumor tissue.

References

Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, Baselga J. 1997. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966–1972.

Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, et al. 2003. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21:291–297.

Carney DN. 1996. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 23:71–75.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. 2004. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084–2091.

Cleare MJ, Hydes PC, Malerbi BW, Watkins DM. 1978. Anti-tumor platinum complexes: Relationships between chemical properties and activity. Biochimie 60:835–850.

Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413–1418.

Douillard JY, Cunningham D, Roth AD, et al. 2000. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041–1047.

du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. 2003. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329.

Gallo RC, Whang-Peng J, Adamson RH. 1971. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789–795.

Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. 1970. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461–470.

Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, et al. 1999. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 80:364–370.

Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. 1997. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844–1852.

Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. 1997. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844–1852.

Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. 1993. Block copolymer micelles as vehicles for drug delivey. J Controlled Release 24:119–132.

Kato K, Hamaguchi T, Matsumura Y, Yasui H, Okusaka T, Ueno H, Ikeda M, Muro K, Shirao K, Shimada Y. 2018. Phase I study of NK105, polymer micelle paclitaxel, in patients with advanced cancer. Proc Am Soc Clin Oncol 25:2006.

Khayat D, Antoine EC, Coeffic D. 2000. Taxol in the management of cancers of the breast and the ovary. Cancer Invest 18: 242–260.

Koizumi F, Kitagawa M, Negishi T, et al. 2006. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048–10056.

Li LH, Fraser TJ, Olin EJ, Bhuyan BK. 1972. Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643–2650.

Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392.

Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56:515–521.

Nakajima T, Matsumura Y. 2007. Abstr 4729 Synergictic antitumor activity of novel polymeric micelles incorporating SN-38(NK102) in combination with 5-fluorouracil (5-FU) in mouse model of colon cancer. Proc Am Assoc Cancer Res 98.

Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, et al. 2003. CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88: 335–341.

Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. 2003. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977–8983.

Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. 2002. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91.

Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P. 1994. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review. Cancer Chemother Pharmacol 35:1–9.

Roth BJ. 1996. Chemotherapy for advanced bladder cancer. Semin Oncol 23:633–644, Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD and Baguley BC (2000). Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer, 82, 966–72.

Rothenberg ML, Kuhn JG, Burris HA, 3rd, Nelson J, Eckardt JR, Tristan-Morales M, et al. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194–2204.

Rowinsky EK, Donehower RC. 1995. Paclitaxel (taxol). N Engl J Med 332:1004–1014, Savic R, Luo L, Eisenberg A, Maysinger D (2003). Micellar nanocontainers distribute to defined cytoplasmic organelles. Science, 300, 615–8.

Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC. 1993. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010–2020.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. 2000. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914.

Saltz LB, Douillard JY, Pirotta N, et al. 2001. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist 6:81–91.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, et al. 2000. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 28: 423–433.

Takimoto CH, Arbuck SG. 2001. Topoisomerase I targeting agents: The camptothecins. In: Chabner BA, Lango DL, editors. Cancer chemotherapy and biotherapy: Principal and practice. 3rd ed., Philadelphia (PA): Lippincott Williams & Wilkins. p 579–646.

Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. 2005. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678–687.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J. 1996. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity. J Clin Oncol 14:1993–1999.

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. 1990. Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268.

Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S. 1990. Polymer micelles as novel drug carrier: Adriamycin-conjugted poly(ethylene glycol)-poly(aspartic acid) block copolymer. J Controlled Release 11:269–278.

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. 1991. Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51:3229–3236.

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. 1991. Toxicity and antitumour activity against solid tumours of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51:3229–3236.

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. 1991. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51:3229–3236.

J Hum Genet (2007) 52:804–819
DOI 10.1007/s10038-007-0186-6

ORIGINAL ARTICLE

Genetic variations and haplotype structures of the *DPYD* gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences

Keiko Maekawa · Mayumi Saeki · Yoshiro Saito · Shogo Ozawa · Kouichi Kurose · Nahoko Kaniwa · Manabu Kawamoto · Naoyuki Kamatani · Ken Kato · Tetsuya Hamaguchi · Yasuhide Yamada · Kuniaki Shirao · Yasuhiro Shimada · Manabu Muto · Toshihiko Doi · Atsushi Ohtsu · Teruhiko Yoshida · Yasuhiro Matsumura · Nagahiro Saijo · Jun-ichi Sawada

Received: 30 May 2007 / Accepted: 26 July 2007 / Published online: 9 September 2007

Abstract Dihydropyrimidine dehydrogenase (DPD) is an inactivating and rate-limiting enzyme for 5-fluorouracil (5-FU), and its deficiency is associated with a risk for developing a severe or fatal toxicity to 5-FU. In this study, to search for genetic variations of *DPYD* encoding DPD in Japanese, the putative promoter region, all exons, and flanking introns of *DPYD* were sequenced from 341 subjects including cancer patients treated with 5-FU. Fifty-five genetic variations, including 38 novel ones, were found and consisted of 4 in the 5′-flanking region, 21 (5 synonymous and 16 nonsynonymous) in the coding exons, and 30 in the introns. Nine novel nonsynonymous SNPs, 29C>A (Ala10Glu), 325T>A (Tyr109Asn), 451A>G (Asn151Asp), 733A>T (Ile245Phe), 793G>A (Glu265Lys), 1543G>A (Val515Ile), 1572T>G (Phe524Leu), 1666A>C (Ser556-Arg), and 2678A>G (Asn893Ser), were found at allele frequencies between 0.15 and 0.88%. Two known nonsynonymous variations reported only in Japanese, 1003G>T (**11*, Val335Leu) and 2303C>A (Thr768Lys), were found at allele frequencies of 0.15 and 2.8%, respectively. SNP and haplotype distributions in Japanese were quite different from those reported previously in Caucasians. This study provides fundamental information for pharmacogenetic studies for evaluating the efficacy and toxicity of 5-FU in Japanese and probably East Asians.

Keywords *DPYD* · SNP · Haplotype · Japanese · 5-fluorouracil

K. Maekawa (✉) · Y. Saito · J. Sawada
Division of Biochemistry and Immunochemistry,
National Institute of Health Sciences,
1-18-1 Kamiyoga, Setagaya-ku,
Tokyo 158-8501, Japan
e-mail: maekawa@nihs.go.jp

K. Maekawa · M. Saeki · Y. Saito · S. Ozawa · K. Kurose · N. Kaniwa · J. Sawada
Project Team for Pharmacogenetics,
National Institute of Health Sciences, Tokyo, Japan

S. Ozawa
Division of Pharmacology,
National Institute of Health Sciences, Tokyo, Japan

K. Kurose · N. Kaniwa
Division of Medicinal Safety Science,
National Institute of Health Sciences, Tokyo, Japan

M. Kawamoto · N. Kamatani
Division of Genomic Medicine,
Department of Advanced Biomedical Engineering and Science,
Tokyo Women's Medical University, Tokyo, Japan

K. Kato · T. Hamaguchi · Y. Yamada · K. Shirao · Y. Shimada
Gastrointestinal Oncology Division, National Cancer Center Hospital, National Cancer Center, Tokyo, Japan

M. Muto
Gastrointestinal Oncology Division,
National Cancer Center Hospital East, Kashiwa, Japan

T. Doi · A. Ohtsu
Division of GI Oncology/Digestive Endoscopy,
National Cancer Center Hospital East, Kashiwa, Japan

T. Yoshida
Genetics Division, National Cancer Center Research Institute,
National Cancer Center, Tokyo, Japan

Y. Matsumura
Research Center of Innovative Oncology,
National Cancer Center Hospital East, Kashiwa, Japan

N. Saijo
Deputy Director, National Cancer Center Hospital East, Kashiwa, Japan

Introduction

Dihydropyrimidine dehydrogenase (DPD) is an inactivating and rate-limiting enzyme for 5-fluorouracil (5-FU), which is used in various therapeutic regimens for gastrointestinal, breast and head/neck cancers (Grem 1996). While the antitumor effect of 5-FU is exerted via anabolic pathways responsible for its intracellular conversion into anti-proliferative nucleotides, DPD affects 5-FU availability by rapidly degrading it to 5, 6-dihydrofluorouracil (DHFU) (Heggie et al. 1987). The importance of DPD in 5-FU metabolism was also highlighted by a lethal drug interaction between 5-FU and the antiviral agent sorivudine. Due to inhibition of DPD by a sorivudine metabolite, severe systemic exposure to 5-FU caused several acute deaths in Japan (Nishiyama et al. 2000).

5-FU catabolism occurs in various tissues, including tumors, but is highest in the liver (Naguib et al. 1985; Lu et al. 1993). Wide variations in DPD activity (8- to 21-fold) were shown in Caucasians, and 3–5% of Caucasians had reduced DPD activity (Etienne et al. 1994; Lu et al. 1998). This variability, which is partially attributed to genetic defects of the DPD gene (*DPYD*), leads to differential responses of cancer patients, resistance to or increased toxicity of 5-FU (van Kuilenburg 2004). Complete DPD deficiency is also associated with the inherited metabolic disorder, thymine-uraciluria, which is characterized by neurological problems in pediatric patients (Bakkeren et al. 1984).

To date, at least 30 variant *DPYD* alleles have been published, with or without deleterious impact upon DPD activity (Gross et al. 2003; Ogura et al. 2005; Seck et al. 2005; van Kuilenburg 2004; Zhu et al. 2004). Of these variations, a splice site polymorphism, IVS14 + 1G>A, which causes skipping of exon 14, is occasionally detected in North Europeans with allele frequencies of 0.01–0.02 (van Kuilenburg 2004). Detection of IVS14 + 1G>A in patients suffering from 5-FU-associated grade 3 or 4 toxicity revealed that 24–28% of them were heterozygous or homozygous for this single nucleotide polymorphism (SNP) (van Kuilenburg 2004). However, this SNP has not been reported in Japanese and African-Americans. Recently, Ogura et al. (2005) have shown that a Japanese population exhibits a large degree of interindividual variations in DPD activity of peripheral blood mononuclear cells. They also identified a novel variation, 1097G>C (Gly366Ala), in a healthy volunteer with the lowest DPD activity and demonstrated that the 366Ala variant has reduced activity towards 5-FU in vitro. At present, however, information on variant alleles with clinical relevance in Japanese is limited and cannot fully explain polymorphic DPD activity.

In this study, we searched for genetic variations in *DPYD* by sequencing 5′ regulatory regions, all exons and surrounding introns from 341 Japanese subjects. Fifty-five variations including nine novel nonsynonymous ones were identified. Then, linkage disequilibrium (LD) and haplotype analyses were performed to clarify the *DPYD* haplotype structures in Japanese.

Materials and methods

Human DNA samples

Three hundred and forty-one Japanese subjects in this study included 263 cancer patients and 78 healthy volunteers. All 263 patients were administered 5-FU or tegafur for treatment of various cancers (mainly stomach and colon) at the National Cancer Center, and blood samples were collected prior to the fluoropyrimidine chemotherapy. The healthy volunteers were recruited at the Tokyo Women's Medical University. DNA was extracted from the blood of cancer patients and Epstein-Barr virus-transformed lymphoblastoid cells derived from healthy volunteers. Written informed consent was obtained from all participating subjects. The ethical review boards of the National Cancer Center, the Tokyo Women's Medical University and the National Institute of Health Sciences approved this study.

PCR conditions for DNA sequencing

To amplify 22 exons (exons 2–23) of *DPYD*, multiplex PCRs were performed by using four sets of mixed primers (mix 1 to mix 4 of "first PCR" in Table 1). Namely, five exonic fragments were simultaneously amplified from 50 ng of genomic DNA using 0.625 units of Ex-Taq (Takara Bio. Inc., Shiga, Japan) with 0.20 μM primers. Because of the high GC content in exon 1 of *DPYD*, this region was separately amplified from 50 ng of genomic DNA with 2.5 units of LA-Taq and 0.2 μM primers (listed in Table 1) in GC buffer I (Takara Bio. Inc.). The first PCR conditions were 94°C for 5 min, followed by 30 cycles of 94°C for 30 s, 58°C for 1 min, and 72°C for 2 min; and then a final extension for 7 min at 72°C. Next, each exon was amplified separately from the first PCR products by nested PCR (2nd PCR) using the primer sets (0.2 μM) listed in "second PCR" of Table 1. The second PCR conditions were the same as those of the first PCR, and LA-Taq (2.5 units) for exon 1 and Ex-Taq (0.625 units) for exons 2–23 were used. All PCR primers were designed in the flanking intronic sites to analyze the exon-intron splice junctions. The PCR products were treated with a PCR Product Pre-Sequencing Kit (USB Co., Cleveland, OH) and sequenced directly on both strands using an ABI BigDye Terminator Cycle Sequencing Kit (Applied Biosystems,

Table 1 Primer sequences for human *DPYD*

Amplified and sequenced region			Forward primer		Reverse primer		PCR product (bp)
			Sequences (5' to 3')	Position[a]	Sequences (5' to 3')	Position[a]	
First PCR	5'-UTR to exon 1		GTTCTGGAAGGTAATCTGATGG	52207178	ACGACATACAGGAGGTGAAG	52205443	1,736
	Mix 1	Exon 2	CTACTTGGGAGACTAAGGTG	52168526	GTATCATTGTGTCATTAGGC	52167832	695
		Exon 3	TCCCTTCATCTTAGTCAATG	52113605	CTGAGGCTTAACATTTATGC	52112876	730
		Exon 4	TCTGAGAGGAGGGACAGTTA	52025660	AATCACAACTTGGAAGTGCT	52025165	496
		Exon 5	AAATGGAGGATAACCTGAGT	52007046	TAATAACCTGCTGGGATTGC	52006234	813
		Exon 6	AGAGGAGAGGCACTTAATGT	51984772	TGCTTCAAGCCAACTGCAAA	51984115	658
	Mix 2	Exon 7	CTCAAATAATAGTGCCATAGG	51977410	CAGTAGACAGACAAATGCCC	51976498	913
		Exon 8	CACATCGTGCTTTGAACATA	51964415	CCAACTCCATCCTTTATGAT	51963667	749
		Exons 9 and 10	TGAGGCAAGAATATAACCTG	51880431	TCCGTATGTGTCTTATTACC	51877795	2,637
		Exon 11	AGAAATACCTTATGATGCCG	51859160	GCCTTTTGAATCAAGATTGC	51858562	599
		Exon 16	CTCCCTATGCTTCAGTTCAC	51658925	TGCCGTGCCCCATTTACTAC	51658114	812
	Mix 3	Exon 12	CCGCTCTGAAACATTGACCA	51834944	CTGGGATTATAGGCATTAGG	51834279	666
		Exon 13	GCCCATATCTCTGAGCACTA	51801258	ATCTTTGTTGCTTCCTAGAC	51800450	809
		Exon 14	CCTTCACTGATTTACATCGG	51735640	CCAGCCACATACAGTGAAAA	51734704	937
		Exon 15	AGCCAGTAAAATCCTCTCTA	51667711	TATGGAAAACCTGCTGACTA	51666815	897
		Exon 23	TGGAAAGACCCGAACTCTGC	51364409	AGCGAAGGGGATTTTACTTA	51363336	1,074
	Mix 4	Exons 17 and 18	TTCTAAAGGCTCTGTTGAGG	51591491	TGGCAAAAGAACTGAGAGAC	51589933	1,559
		Exon 19	CGTGGATTCAAGCAGTTTTC	51520500	AGACAGTGGGTTCGTAAGCC	51519586	915
		Exon 20	CTGTGACACCATTACCATTG	51478435	TGCCAGTCATCACCACAGTA	51477733	703
		Exon 21	GAACCTGATACCGAGAAGAC	51383758	AAATGTCCAGGCTTTCCAGA	51382987	772
		Exon 22	GCCATAACAACTCACACGGG	51367740	TTGGCAGAAGGAATCATAGC	51366885	856
Second PCR		5'-UTR to exon 1	TGTGGATGTTTTTGCTCGC	52206503	AGTAAACAGGTCCCGACGC	52205586	918
		Exon 2	GTGAACTGAGATTGTACCACTGC	52168471	CATATCCCTTATCAAAAATGCTT	52167924	548
		Exon 3	GAATGCTACCCAATTAAAGTGG	52113285	TTCAAAACCAAATACAGCCTC	52112899	387
		Exon 4	TGCCAAAGATGAAACACAGA	52025601	ACCCACAGATAATAGAGAACAAGA	52025273	329
		Exon 5	TGATGGTTCCTGATAGTAGTATTG	52006775	TGTCACACTAAAAATGTTGGG	52006348	428
		Exon 6	AAGGAAAGACTGAAAGTTAGCC	51984688	GAGCCTGAAGTTCCTATATGAT	51984201	488
		Exon 7	TTCTACTGTATCTTCACTCCACG	51976953	GCTTCTGCCTGATGTAGC	51976541	413
		Exon 8	GGCTGACTTTTCATTCTTTTT	51964221	CATCTTGCCGAAATCTCTCC	51963831	391
		Exon 9	TGTGATTTACGATGTGTACTTGG	51880335	GCAAGGTTGGGTGTGAGAG	51879895	441
		Exon 10	AAAATGGGAATAAAACTGTCTT	51878507	TCAGGATATGGAAGACTTAGCAC	51877859	649
		Exon 11	ACTGGTAACTGAAACTCAG	51859069	CAATTCCCTGAAAGCTAG	51858628	442
		Exon 12	TCAGTGCCCTTCAAATGTGT	51834881	ACCAAATAGAAATGCTCTTATAGA	51834414	468
		Exon 13	TCGGATGCTGTGTTGAAGTG	51800982	TGTGTAATGATAGGTCGTGTC	51800543	440

Table 1 Primer sequences for human *DPYD*

Amplified and sequenced region		Forward primer		Reverse primer		PCR product (bp)
		Sequences (5' to 3')	Position[a]	Sequences (5' to 3')	Position[a]	
	Exon 14	TGCAAATATGTGAGGAGGGACC	51735287	CAGCAAAGCAACTGGCAGATTC	51734877	411
	Exon 15	GCTATCTTACCCTGCTATTTTC	51667571	TAGGTAGTGTGTGAAATCCAAGG	51667107	465
	Exon 16	CCCCTTATGAGCACTGAGTAAAT	51658821	TAGTAACTATCCATACGGGGG	51658440	382
	Exon 17	AGTCTAGGTGTAATACTGAGGAGG	51591407	ATCAAGTGCTCAACTGGAAACT	51590986	422
	Exon 18	GTGAAGAACTTTGAGGAGAAGAC	51590461	CATCCTGTGCTGTCACTTGA	51590026	436
	Exon 19	ATTTGTCCAGTGACGCTGTC	51520048	TCAGGTCTCTTCATAACTTGTCAG	51519629	420
	Exon 20	GAGAAGTGAATTTGTTTGGAG	51478265	TTTGTTAGTGAGAATGTGAGATGG	51477926	340
	Exon 21	AGTGGTCCAAAACAATGAGTG	51383737	TGCTTGCCAGTGTTCTAAAA	51383221	517
	Exon 22	GGGTGTCATTTATTCTTTCTGTC	51367723	GGCTGATGAAATGGTATAAAAA	51367033	691
	Exon 23	GTTGTCTCATAGTGTGGCTCCTC	51364206	TTTTTCACATAAGACAACTGGCA	51363641	566
Sequencing	5'-UTR to exon 1	TGTGGATGTTTTTGCTCGC	52206503			
	5'-UTR to exon 1	CGGACTGCTTTTACCTTTGC	52206258	CCAGAGAGCCAAGTGACAGC	52205933	
	5'-UTR to exon 1	CCCTAGTCTGCCTGTTTTCG	52205987	AGTAAACAGGTCCCGACGC	52205586	
	Exon 2	GTGACAAAGTGAGAGAGACCGT	52168436	GCCTTACAATGTGTGGAGTGAG	52168152	
	Exon 3	GAATGCTACCCAATTAAAGTGG	52113285	TTCAAAACCAAATACAGCCTC	52112899	
	Exon 4	TGCCAAAGATGAAACACAGA	52025601	ACCCACAGATAATAGAGAACAAGA	52025273	
	Exon 5	TGATGGTTCCTGATAGTAGTATTG	52006775	TGTCACACTAAAAATGTTGGG	52006348	
	Exon 6	AAAATATGTTTGAGGATGTAAGC	51984560	GAGCCTGAAGTTCCTATATGAT	51984201	
	Exon 7	TTCTACTGTATCTTCACTCCACG	51976953	GCTTCTGCCTGATGTAGC	51976541	
	Exon 8	GGCTGACTTTTCATTCTTTTT	51964221	CATCTTGCCGAAATCTCTCC	51963831	
	Exon 9	TGTGATTTACGATGTGTACTTGG	51880335	GCAAGGTTGGGTGTGAGAG	51879895	
	Exon 10	AAAATGGGAATAAAACTGTCTT	51878507	TTCATCTCCTAAAATCTGTTGG	51878109	
	Exon 11	ACTGGTAACTGAAACTCAG	51859069	CAATTCCCTGAAAGCTAG	51858628	
	Exon 12	TCAGTGCCCTTCAAATGTGT	51834881	GAGTATCAAAAATAAATGAAGCAC	51834439	
	Exon 13	TCGGATGCTGTGTTGAAGTG	51800982	TGTGTAATGATAGGTCGTGTC	51800543	
	Exon 14	TGCAAATATGTGAGGAGGGACC	51735287	CAGCAAAGCAACTGGCAGATTC	51734877	
	Exon 15	GCTATCTTACCCTGCTATTTTC	51667571	TAGGTAGTGTGTGAAATCCAAGG	51667107	
	Exon 16	CCCCTTATGAGCACTGAGTAAAT	51658821	TAGTAACTATCCATACGGGGG	51658440	
	Exon 17	AGTCTAGGTGTAATACTGAGGAGG	51591407	ATCAAGTGCTCAACTGGAAACT	51590986	
	Exon 18	GTGAAGAACTTTGAGGAGAAGAC	51580461	CATCCTGTGCTGTCACTTGA	51590026	
	Exon 19	ATTTGTCCAGTGACGCTGTC	51520048	CGAATCTATTTTTTTTTTGTCAC	51519715	
	Exon 20	GAGAAGTGAATTTGTTTGGAG	51478265	TTTGTTAGTGAGAATGTGAGATGG	51477926	
	Exon 21	TATCTTCCCATTTTTCTCTTCTC	51383644	TGCCAGTGTTCTAAAAAGTATAAA	51383225	
	Exon 22	GTATAAAAACAGGAAAATGCTGA	51367510	ATAAGGGTGACAGGACAGAAAG	51367125	
	Exon 23	GTTGTCTCATAGTGTGGCTCCTC	51364206	TATTTGTTTTAATTTGGAAAGAG	51363821	

[a] Nucleotide position of the 5' end of each primer on NT_032977.7

Foster City, CA) with the primers listed in "sequencing" of Table 1. Excess dye was removed with a DyeEx96 kit (Qiagen, Hilden, Germany). The eluates were analyzed on an ABI Prism 3700 DNA Analyzer (Applied Biosystems). All novel SNPs were confirmed by sequencing of PCR products generated from new genomic DNA amplifications. The genomic and cDNA sequences of *DPYD* obtained from GenBank (NT_032977.7 and NM_000110.2, respectively) were used as reference sequences. SNP positions were numbered based on the cDNA sequence, and adenine of the translational initiation site in exon 1 was numbered +1. For intronic polymorphisms, the position was numbered from the nearest exon.

Linkage disequilibrium (LD) and haplotype analyses

Hardy-Weinberg equilibrium and LD analyses were performed by SNPAlyze software (Dynacom Co., Yokohama, Japan), and pairwise LD parameters between variations were obtained as the |D'| and rho square (r^2) values. Some haplotypes were unambiguously identified from subjects with homozygous variations at all sites or a heterozygous variation at only one site. Diplotype configurations were inferred by LDSUPPORT software, which determines the posterior probability distribution of the diplotype for each subject based on the estimated haplotype frequencies (Kitamura et al. 2002). Although the nomenclature for nonsynonymous *DPYD* alleles (*DPYD*1* to *DPYD*13*) have been already publicized (McLeod et al. 1998; Collie-Duguid et al. 2000; Johnson et al. 2002), several reported alleles remain unassigned. To avoid confusion with the previous *DPYD* allele nomenclature, our block haplotypes in this study were tentatively defined by using '#' instead of '*'. A group of haplotypes without any amino acid change is designated as *#1*, and the haplotype groups bearing already defined alleles, *DPYD*5* (Ile543Val), *DPYD*6* (Val732Ile), *DPYD*9* (Cys29Arg) and *DPYD*11* (Val335Leu), were numbered by using the corresponding Arabic numerals, *#5*, *#6*, *#9*, and *#11*, respectively. Other haplotypes with known nonsynonymous SNPs such as 496A>G (Met166Val) or with the novel nonsynonymous SNP were represented by '#' plus amino acid positions followed by variant residues (for example, *#166V*). Subtypes within each haplotype group were consecutively named with small alphabetical letters depending on their frequencies. Haplotypes ambiguously inferred in only one patient were indicated in the Fig. 3 legend. Combinations of block haplotypes were analyzed by Haploview software (http://www.broad.mit.edu/mpg/haploview/index.php) (Barrett et al. 2005), and the long-range (whole gene) haplotypes spanning all blocks were inferred by Hapblock software (www.cmb.usc.edu/msms/HapBlock/) (Zhang et al. 2005).

Typing data on *DPYD* from unrelated 44 Japanese and 30 Caucasian trios were also obtained from the HapMap project (HapMap release 19: http://www.hapmap.org/). The LD profiles and haplotypes of the HapMap data were obtained by Marker beta in Gmap Net (http://www.gmap.net/marker) using its four (1254711, 1254712, 1254713, and 1254714) and six (1166276, 1166277, 1166278, 1166279, 1166280, and 1166281) datasets covering *DPYD* genomic regions for Japanese and Caucasians, respectively.

Drawing of protein structures

The coordinate data (1gth) of the crystal structure of pig DPD (Dobritzsch et al. 2002) was obtained from the Protein Data Bank. Protein Explorer (http://proteinexplorer.org) (Martz 2002) was used to display the structural features of pig DPD and depict three-dimensional views.

Results

DPYD variations found in a Japanese population

We identified 55 variations, including 38 novel ones by sequencing the promoter regions (up to 613 bp upstream from the translational initiation site), all 23 exons and their flanking regions of *DPYD* from 341 Japanese subjects (Table 2). The distribution of the variations consisted of 4 in the 5' flanking region, 21 (5 synonymous and 16 nonsynonymous ones) in the coding exons (Fig. 1) and 30 in the introns. Since we did not find any significant differences in allele frequencies between healthy volunteers and cancer patients ($P > 0.05$ by χ^2 test or Fisher's exact test) except for one variation, IVS14 + 19C>A, ($P = 0.027$ by Fisher's exact test); the data for all subjects were analyzed as one group. All detected variations except for 451A>G (Asn151Asp) and IVS13 + 40G>A were in Hardy-Weinberg equilibrium ($P \geq 0.24$).

Thirteen novel variations in the coding region (enclosed by a square in Fig. 1) contain four synonymous SNPs, 474T>C (Phe158Phe), 639C>T (Asp213Asp), 1752A>G (Thr584Thr), and 2424T>C (Ser808Ser) and nine nonsynonymous SNPs, 29C>A (Ala10Glu), 325T>A (Tyr109Asn), 451A>G (Asn151Asp), 733A>T (Ile245Phe), 793G>A (Glu265Lys), 1543G>A (Val515Ile), 1572T>G (Phe524-Leu), 1666A>C (Ser556Arg), and 2678A>G (Asn893Ser). 451A>G (Asn151Asp), 325T>A (Tyr109Asn), and 2678A>G (Asn893Ser) were found at frequencies of 0.009, 0.003 and 0.003, respectively. The others were detected as single heterozygotes (allele frequencies = 0.0015).